Tower Research Capital (TRC)’s BriaCell Therapeutics BCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTX
SM
Tower Research Capital (TRC)'s BCTX Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of BriaCell Therapeutics (BCTX) in Q1 2026, closing a stake of 9 shares — an estimated $64 sold.
Tower Research Capital (TRC) first reported a position in BCTX in Q2 2021 and held it in 15 quarters. The position peaked at $38K in Q4 2021. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining BriaCell Therapeutics position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 9 BriaCell Therapeutics shares in Q1 2026, an estimated $64.
- Tower Research Capital (TRC) first reported a position in BriaCell Therapeutics in Q2 2021 and held it in 15 quarters.
- Tower Research Capital (TRC)'s BriaCell Therapeutics position peaked at $38K in Q4 2021.
- 16 funds tracked by Wall St. Rank held BriaCell Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.